See more : Fushiki Kairiku Unso Co.,Ltd. (9361.T) Income Statement Analysis – Financial Results
Complete financial analysis of CinCor Pharma, Inc. (CINC) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CinCor Pharma, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Hisamitsu Pharmaceutical Co., Inc. (HTSUF) Income Statement Analysis – Financial Results
- Suzhou Basecare Medical Corporation Limited (2170.HK) Income Statement Analysis – Financial Results
- Xinjiang Haoyuan Natural Gas Co. ,Ltd. (002700.SZ) Income Statement Analysis – Financial Results
- Expeditors International of Washington, Inc. (EW1.DE) Income Statement Analysis – Financial Results
- Peel Hunt Limited (PEEL.L) Income Statement Analysis – Financial Results
CinCor Pharma, Inc. (CINC)
About CinCor Pharma, Inc.
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases. It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases. CinCor Pharma, Inc. has a license agreement with F. Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
| Metric | 2021 | 2020 | 2019 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% |
| Research & Development | 21.51M | 17.95M | 3.93M |
| General & Administrative | 21.00M | 3.17M | 1.21M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 |
| SG&A | 21.00M | 3.17M | 1.21M |
| Other Expenses | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 42.51M | 21.13M | 5.14M |
| Cost & Expenses | 42.51M | 21.13M | 5.14M |
| Interest Income | 21.64K | 36.73K | 101.71K |
| Interest Expense | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 7.88M | 1.21M | 171.86K |
| EBITDA | -34.63M | -19.92M | -5.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% |
| Operating Income | -42.51M | -21.13M | -5.14M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -7.86M | -1.17M | 101.71K |
| Income Before Tax | -50.37M | -22.30M | -5.04M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -21.64K | -36.73K | -101.71K |
| Net Income | -50.35M | -22.26M | -4.93M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% |
| EPS | -1.42 | -0.95 | -0.21 |
| EPS Diluted | -1.42 | -0.95 | -0.21 |
| Weighted Avg Shares Out | 35.42M | 23.49M | 23.49M |
| Weighted Avg Shares Out (Dil) | 35.42M | 23.49M | 23.49M |
These Are the 10 Best-Performing IPOs in 2022 Through October
The IPO market has been slow this year as investors' risk appetite for new issues hit a record low.
CinCor Pharma to Participate at Upcoming September Investor Conferences
WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17th Annual BioPharma Conference taking place September 6 - 8, 2022 in Boston, MA...
7 No-Brainer Biotech Stocks to Add to Your Buy List
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first on InvestorPlace.
CinCor Pharma Begins Patient Dosing In Midstage Hypertension, Kidney Disease Study
CinCor Pharma (NASDAQ: CINC) has dosed first patient in the figHTN-CKD Phase 2 clinical study of its drug candidate Baxdrostat (CIN-107) for the treatment of patients with uncontrolled hypertension and chronic kidney disease (CKD). The figHTN-CKD trial is a randomised...
CinCor Pharma to Present at the Jefferies Healthcare Conference
WALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a...
CinCor Pharma to Present at Upcoming Investor Conferences
WALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at the...
CinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022
BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that it will report its...
CinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare Conference
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today announced that its management team will...
10 Best Stocks to Buy on the Nasdaq Right Now
With the technology-centric Nasdaq having a rough time of things, this sets up possible attractive discounts for stocks to buy. The post 10 Best Stocks to Buy on the Nasdaq Right Now appeared first on InvestorPlace.
U.S. IPO Weekly Recap: Biotechs Ring In The New Year In A 4 IPO Week
The IPO market kicked off the new year with three biotechs and an online home goods retailer, joined by four SPACs. Four SPACs went public led by Sagansky and Sloan's Screaming Eagle Acquisition, which raised $750 million.
Source: https://incomestatements.info
Category: Stock Reports